Overview

Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia

Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Women with provoked vestibulodynia (PVD) suffer from severe dyspareunia and often present a hyperactivity of the pelvic floor muscles (PFM) which maintain the dyspareunia. The rationale for the study is that for women with PVD who don't succeed to restore the function of the PFM by physiotherapy, Botulinum Toxin A (BTA) could be an optional treatment by decreasing the high muscle tonus and thus possibly reduce the coital pain.
Phase:
Phase 3
Details
Lead Sponsor:
Karolinska Institutet
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
incobotulinumtoxinA
onabotulinumtoxinA